

India Equity Institutional Research II

Result Update - Q2FY23

II 21st October 2022

Page 2

## Colgate Palmolive (India) Ltd.

Sequential gross margin pressure mitigated by lower opex

Coigate Fairnoilve (India)

INR 1,607 INR 1,753

Target Potential Upside INR 1,753 9.1%

Market Cap (INR Mn)
INR 4,37,081

Recommendation **ACCUMULATE** 

Sector

Consumer Goods

### Result Highlights of Q2FY23

- In Q2FY23, CLGT reported revenue of INR 13,875 mn (+2.6% YoY/ +15.9% QoQ). For H1FY23, revenue was at INR 25,843 mn (+2.6% YoY).
- EBITDA for Q2FY23 was INR 4,080 mn (+1.8% YoY/ +25.3% QoQ). EBITDA margin for the quarter was at 29.4%, which was a contraction of 23 bps YoY but an improvement of 219 bps QoQ, despite the pressure on gross margins. EBITDA margin for H1FY23 contracted by 163 bps YoY to 28.4%.
- Adj. Net Profit for Q2FY23 was at INR 2,780 mn (+3.3% YoY/ +26.9% QoQ). Adj. Net profit for H1FY23 declined by 1.1% YoY to INR 4,970 mn.

#### **MARKET DATA**


Shares outs (Mn)	272
Mkt Cap (INR mn)	4,37,081
52 Wk H/L (INR)	1,696/1,376
Volume Avg (3m K)	302
Face Value (INR)	1
Bloomberg Code	CLGT IN

#### **KEY FINANCIALS**

INR Millions	FY20	FY21	FY22	FY23E	FY24E
Revenue	45,251	48,412	50,998	53,705	58,493
EBITDA	12,017	15,096	15,659	15,842	18,085
PAT	8,165	10,354	10,783	10,844	12,488
Adj PAT	8,165	10,354	10,783	10,937	12,488
EPS (INR)	30.0	38.1	39.6	39.9	45.9
Adj. EPS (INR)	30.0	38.1	39.6	40.2	45.9
EBITDA Margin (%)	26.6%	31.2%	30.7%	29.5%	30.9%
NPM (%)	18.0%	21.4%	21.1%	20.2%	21.3%

Source: Company, KRChoksey Research

#### **SHARE PRICE PERFORMANCE**



#### Revenue growth continues to be in the low single digits

CLGT's revenues improved by 2.6% YoY and 15.9% QoQ in Q2FY23, which is a seasonally strong quarter for the company. The YoY growth remained near the levels seen in Q1FY23 of 2.5% YoY.

#### Sequential EBITDA margin improvement is seen despite gross margin pressure

In Q2FY23, gross margins declined by 308 bps YoY and 257 bps QoQ. The pressure on gross margins was mitigated by lower operating costs. Employee costs, advertising costs, and other expenses combined as a % of sales declined by 285 bps YoY and 476 bps QoQ. The cost savings led to EBITDA margins improving sequentially by 219 bps to 29.4% in the quarter. On a YoY basis, the EBITDA margin still remained under pressure, with a contraction of 23 bps.

### Change in management

Prabha Narsimhan joined as Managing Director and CEO effective September 1, 2022. She brings with her nearly 25 years of experience across Customer Development, Consumer Marketing and Innovation across geographies and multiple categories.

### Interim dividend declared

CLGT's Board of directors declared a first Interim Dividend of INR 18 per share of face value INR 1 each for FY23.

#### Outlook

The management has seen improved momentum driven by the focused deployment of initiatives during the festive season. The management remains cautiously optimistic about the overall growth trend, especially in rural. The growth in modern trade and e-commerce businesses has been encouraging. As the macroeconomic environment stabilizes, CLGT is expected to focus on delivering sustainable gross margins. CLGT plans to continue to invest in the core while driving premiumization and category expansion into personal care.

### MARKET INFO

SENSEX	59,203
NIFTY	17,564

### SHARE HOLDING PATTERN (%)

Particulars	Sep-22	Jun-22	Mar-22
Promoters	51.0	51.0	51.0
FIIs	19.5	18.7	18.6
DIIs	9.3	8.8	8.3
Others	20.3	21.5	22.1
Total	100.0	100	100

7.1%

Revenue CAGR between FY22 and FY24E

7.6%

PAT CAGR between FY22 and FY24E

India Equity Institutional Research II

# Colgate Palmolive (India) Ltd.


#### Valuation & view:

CLGT's core brands like Colgate Strong Teeth, Colgate MaxFresh and Colgate Active Salt continued to report healthy growth. Visible White O2 has delivered a very strong performance across quarters since its launch. CLGT launched MaxFresh Charcoal in the quarter and has a further pipeline of innovative products. Also, there is continued impetus on Palmolive Face wash and Electric toothbrushes.


CLGT has reported low single-digit YoY growth in each quarter since Q3FY22. The trend has continued in Q2FY23. As the benefit of commodity costs softening comes through, we expect some revival in demand in the coming quarters. CLGT has managed to optimize their operating costs in Q2FY23, but we think some operating expenses like ad spends can come back. As gross margins improve, we should see improvement in the EBITDA margins despite some increase in ad spends of other opex. We estimate CLGT's Revenue/EBITDA/PAT to grow at a CAGR of 7.1% / 7.5% / 7.6% over FY22-FY24E.

We apply P/E multiple of 38.2x on FY24E EPS of INR 45.9 and arrive at a target price of INR 1,753 per share (unchanged), having an upside potential of 9.1% from CMP. Accordingly, we maintain our rating at "Accumulate" on the shares of Colgate Palmolive India.


### YoY revenue growth continued to be in low singledigits




# EBITDA margin improved QoQ despite gross margin pressure



### NPM improved QoQ



# Advertisement spend as a % of revenue declined YoY and QoQ



Source: Company, KRChoksey Research

# Colgate Palmolive (India) Ltd.

### **KEY FINANCIALS**

Quarterly Income Statement (INR Mn)	Q2FY23	Q1FY23	Q2FY22	QoQ	YoY	H1FY23	H1FY22	YoY
Revenue	13,875	11,968	13,524	15.9%	2.6%	25,843	25,184	2.6%
Total Expenditure	9,795	8,711	9,517	12.4%	2.9%	18,506	17,624	5.0%
Cost of Raw Materials	4,062	3,559	3,529	14.2%	15.1%	7,621	6,637	14.8%
Purchase of Stock	854	662	665	29.1%	28.5%	1,516	1,476	2.7%
Changes in Inv	113	-190	292	-159.5%	-61.3%	-77	-29	162.1%
Employee Cost	945	937	1,047	0.9%	-9.7%	1,882	1,997	-5.7%
Other Expenses	3,820	3,744	3,984	2.0%	-4.1%	7,564	7,544	0.3%
EBITDA	4,080	3,257	4,008	25.3%	1.8%	7,337	7,560	-3.0%
EBITDA Margin (%)	29.4%	27.2%	29.6%	219 bps	-23 bps	28.4%	30.0%	-163 bps
Depreciation	439	442	449	-0.7%	-2.3%	880	896	-1.8%
EBIT	3,641	2,815	3,559	29.3%	2.3%	6,456	6,664	-3.1%
Other Income	113	115	65	-2.3%	73.3%	228	117	94.7%
Interest Expense	13	13	15	-2.3%	-15.3%	26	30	-15.5%
Exceptional items	13,875	11,968	13,524	15.9%	2.6%	25,843	25,184	2.6%
РВТ	3,741	2,824	3,609	32.5%	3.7%	6,566	6,751	-2.7%
Tax	961	727	917	32.1%	4.8%	1,689	1,727	-2.2%
PAT	2,780	2,097	2,692	32.6%	3.3%	4,877	5,024	-2.9%
PAT Margin	20.0%	17.5%	19.9%	252 bps	13 bps	18.9%	19.9%	-108 bps
Adj. PAT	2,780	2,190	2,692	26.9%	3.3%	4,970	5,024	-1.1%
Adj. PAT Margin	20.0%	18.3%	19.9%	174 bps	13 bps	19.2%	19.9%	-72 bps
EPS	10.2	7.7	9.9	32.6%	3.2%	17.9	18.5	-2.9%
Adj. EPS	10.2	8.1	9.9	26.9%	3.3%	18.3	18.5	-1.1%

Source: Company, KRChoksey Research

India Equity Institutional Research ||

Result Update – Q2FY23

|| 21st October 2022

Page 5

# Colgate Palmolive (India) Ltd.

Income Statement (INR Mn)	FY20	FY21	FY22	FY23E	FY24E
Revenues	45,251	48,412	50,998	53,705	58,493
COGS	15,729	15,494	16,675	18,458	18,998
Gross profit	29,522	32,919	34,323	35,248	39,495
Employee cost	3,323	3,656	3,851	3,804	4,272
Other expenses	14,182	14,166	14,812	15,601	17,138
EBITDA	12,017	15,096	15,659	15,842	18,085
EBITDA Margin	26.6%	31.2%	30.7%	29.5%	30.9%
Depreciation & amortization	1,979	1,825	1,773	1,866	2,043
EBIT	10,038	13,271	13,886	13,976	16,042
Interest expense	96	73	59	53	48
Other income	492	304	263	331	336
PBT	10,434	13,502	14,090	14,161	16,330
Tax	2,269	3,148	3,307	3,318	3,842
PAT	8,165	10,354	10,783	10,844	12,488
Adj. PAT	8,165	10,354	10,783	10,937	12,488
EPS (INR)	30.0	38.1	39.6	39.9	45.9
Adj. EPS	30.0	38.1	39.6	40.2	45-9

Cash Flow Statement (INR Mn)	FY20	FY21	FY22	FY23E	FY24E
Net Cash Generated From Operations	8,899	7,839	16,257	12,766	14,238
Net Cash Flow from/(used in) Investing Activities	(187)	714	(1,077)	(1,252)	(2,361)
Net Cash Flow from Financing Activities	(8,514)	(9,565)	(10,906)	(10,640)	(10,904)
Net Inc/Dec in cash equivalents	198	(1,013)	4,275	875	974
Opening Balance	3,780	3,978	2,966	7,240	8,115
Closing Balance Cash and Cash Equivalents	3,978	2,966	7,240	8,115	9,089

Key Ratio	FY20	FY21	FY22	FY23E	FY24E
EBITDA Margin (%)	26.6%	31.2%	30.7%	29.5%	30.9%
Tax rate (%)	21.7%	23.3%	23.5%	23.4%	23.5%
Net Profit Margin (%)	18.0%	21.4%	21.1%	20.2%	21.3%
RoE (%)	51.2%	88.8%	62.2%	61.7%	65.1%
RoCE (%)	66.1%	116.3%	81.5%	81.3%	85.3%
EPS (INR)	30.0	38.1	39.6	39.9	45.9
PE	53.5x	42.2X	40.5x	40.3x	35 <b>.</b> 0x

 ${\tt Source: Company, KRChoksey \, Research}$ 

# Colgate Palmolive (India) Ltd.

Balance Sheet (INR Mn)	FY20	FY21	FY22	FY23E	FY24E
Property, plant and equipment	11,229	10,647	9,630	8,838	8,842
Capital work-in-progress	1,900	1,449	1,218	1,218	1,218
Investments	186	186	0	0	0
Loans	20	14	13	14	15
Other financial assets	177	186	170	179	195
Current tax assets (Net)	2,247	2,583	2,888	3,041	3,312
Other non-current assets	160	102	97	102	112
Total non-current assets	15,919	15,214	14,190	13,575	13,893
Current assets					
Inventories	2,969	3,358	3,572	3 <b>,</b> 762	4,097
Financial assets					
Trade receivables	1,326	1,171	2,247	2,366	2,577
Cash and cash equivalents	3,978	2,966	7,241	8,115	9,089
Bank balances other than (iii) above	235	5,711	307	307	307
Loans	1,135	69	1,073	1,073	1,073
Other financial assets	73	51	70	83	90
Other current assets	405	400	320	987	1,075
Total current assets	10,120	13,726	14,829	16,693	18,308
TOTAL ASSETS	26,040	28,940	29,018	30,268	32,201
EQUITY AND LIABILITIES					
Equity share capital	272	272	272	272	272
Other equity	15,670	11,387	17,075	17,310	18,918
Equity attributable to the equity shareholders	15,942	11,659	17,347	17,582	19,190
Non-controlling interests	0	0	0	0	0
Total equity	15,942	11,659	17,347	17,582	19,190
Non-current liabilities					
Borrowings	0	12	12	12	12
Lease liabilities	840	774	690	690	690
Provisions	488	311	140	161	185
Deferred tax liabilities (Net)	50	0	0	0	0
Other non-current liabilities	17	5	5	5	5
Total non-current liabilities	1,395	1,102	847	868	892
Current liabilities					
Lease liabilities	175	138	140	140	140
Trade payables	6,125	7,604	7,714	8,539	8,789
Other financial liabilities	255	5,811	352	390	401
Other current liabilities	1,034	1,307	1,227	1,358	1,398
Provisions	605	811	840	840	840
Current tax liabilities (Net)	508	508	552	552	552
Total current liabilities	8,703	16,180	10,825	11,818	12,119
Total liabilities	10,098	17,282	11,672	12,686	13,011
TOTAL EQUITY AND LIABILITIES	26,040	28,940	29,018	30,268	32,201

Source: Company, KRChoksey Research

India Equity Institutional Research II

Result Update - Q2FY23

II 21st October 2022

Page 7

# Colgate Palmolive (India) Ltd.

Colgate Palmolive (India) Ltd.			Ltd.	Rating Legend (Expected o	over a 12-month period)
Date	CMP (INR)	TP (INR)	Recommendation	Our Rating	Upside
21-10-22	1,607	1,753	ACCUMULATE		
29-07-22	1,549	1,753	ACCUMULATE	Buy	More than 15%
27-05-22	1,592	1,802	ACCUMULATE	,	
29-01-22	1,400	1,802	BUY	Accumulate	5% – 15%
01-11-21	1,542	1,850	BUY	Accumulate	۰٫۰۰۰ ۱٫۰۰۰
03-08-21	1,674	1,850	ACCUMULATE	Hold	o – 5%
30-06-21	1,670	1,721	HOLD		- J.s
20-05-21	1,606	1,721	ACCUMULATE	Reduce	-5% – o
17-03-21	1,613	1,721	ACCUMULATE		
15-12-20	1,574	1,622	HOLD	Sell	Less than - 5%
23-10-20	1,465	1,622	ACCUMULATE	Jen.	Less than 5/0

#### **ANALYST CERTIFICATION:**

I, Vikrant Kashyap (PGDBM-Finance & IT), Research Analyst, author and the name subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my views about the subject issuer(s) or securities. I also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

#### Terms & Conditions and other disclosures:

KRChoksey Shares and Securities Pvt. Ltd (hereinafter referred to as KRCSSPL) is a registered member of National Stock Exchange of India Limited and Bombay Stock Exchange Limited. KRCSSPL is a registered Research Entity vides SEBI Registration No. INH000001295 under SEBI (Research Analyst) Regulations, 2014.

We submit that no material disciplinary action has been taken on KRCSSPL and its associates (Group Companies) by any Regulatory Authority impacting Equity Research Analysis activities.

KRCSSPL prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analyst covers. The information and opinions in this report have been prepared by KRCSSPL and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of KRCSSPL. While we would endeavor to update the information herein on a reasonable basis, KRCSSPL is not under any obligation to update the information. Also, there may be regulatory, compliance or other reasons that may prevent KRCSSPL from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or KRCSSPL policies, in circumstances where KRCSSPL might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe of or securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. KRCSSPL will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. KRCSSPL accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Our employees in sales and marketing team, dealers and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed herein, In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

Associates (Group Companies) of KRCSSPL might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of brokerage services or specific transaction or for products and services other than brokerage services.

KRCSSPL or its Associates (Group Companies) have not managed or co-managed public offering of securities for the subject company in the past twelve months.

KRCSSPL encourages the practice of giving independent opinion in research report preparation by the analyst and thus strives to minimize the conflict in preparation of research report. KRCSSPL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither KRCSSPL nor Research Analysts have any material conflict of interest at the time of publication of this report.

It is confirmed that, Vikrant Kashyap (PGDBM-Finance & IT), Research Analyst of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific brokerage service transactions.

KRCSSPL or its associates (Group Companies) collectively or its research analyst do not hold any financial interest/beneficial ownership of more than 1% (at the end of the month immediately preceding the date of publication of the research report) in the company covered by Analyst, and has not been engaged in market making activity of the company covered by research

It is confirmed that, Vikrant Kashyap (PGDBM-Finance & IT), Research Analyst do not serve as an officer, director or employee of the companies mentioned in the report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other Jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject KRCSSPL and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform them of and to observe such restriction.

Please send your feedback to research.insti@krchoksey.com Visit us at www.krchoksey.com KRChoksey Shares and Securities Pvt. Ltd

Registered Office:

1102, Stock Exchange Tower, Dalal Street, Fort, Mumbai – 400 001. Phone: +91-22-6633 5000; Fax: +91-22-6633 8060. **Corporate Office:** 

Vikrant Kashyap, research2@krchoksey.com, +91-22-6696 5413

ABHISHEK, 5th Floor, Link Road, Andheri (W), Mumbai – 400 053. Phone: +91-22-6696 5555; Fax: +91-22-6691 9576.